🏢 官网IRCTNMCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:05:00(美东 08-25 16:05)·⟳ 抓取 04:07:50·⚡ 决策 08-26 04:08:48 +58s·62.8 天前
Contineum宣布参加摩根士丹利全球医疗健康会议，未披露临床或财务新增数据
官方来源可信且抓取很早，但事件身份是常规会议日程公告，没有新增临床、监管、财务或交易事实，无法形成正期望交易。
📄 原文CTNM↗ 原文
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET . An audio webcast of the firesi…
不做 Contineum Therapeutics, Inc.（CTNM.US）
不做：官方会议出席通知无新增临床、监管、合作、融资或财务事实，缺少可交易预期差。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Contineum在公司IR和BusinessWire发布参加Morgan Stanley医疗会议的日程，内容只涉及炉边谈话、webcast和公司管线简介；公司此前已在二季报中披露PIPE-791、PIPE-307的关键开发状态和现金 runway，本次没有增量数据或指引，因此不做CTNM.US。
消息传播链
- 公司IR盘后发布参加Morgan Stanley Global Healthcare Conference的会议通知，未含临床或财务新增数据。
- BusinessWire为同一公司稿件的分发版本，未提供超出IR稿的新事实。
关键理由
- 本次公告只提供会议出席和webcast安排，不是临床数据、监管批准、合作授权或融资事件。
- 此前二季报已披露PROPEL-IPF、MOONLIGHT-1和PIPE-791慢性疼痛数据进展，本次没有改变这些里程碑。
主要风险
- 会议期间若管理层额外披露未预期临床或合作信息，需按新事件另行研判。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-30 · 影响 weakens
可见最新实质进展来自此前财报和临床数据公告，本次会议通知未新增临床结果或里程碑。
检索:Contineum Therapeutics PIPE-791 PIPE-307 latest clinical data 2026 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-25 · 影响 none
未发现本次公告包含监管、财务、临床失败或融资稀释等明确负面事实。
检索:Contineum Therapeutics Morgan Stanley conference announcement negative news 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足与事件无增量共同支持不下单，而不是降低仓位后尝试交易。
方向:常规投资者会议出席通知通常不提供可迁移的方向性，除非会议材料同步披露新增临床、订单、合作或指引。
涨幅量级:未取得高相似且有干净首发锚的可交易先例；本事件本身无新增基本面量级，不能据先例外推涨跌幅。
形态:同类会议通知样本主要是日程公告，价格反应更多取决于后续会议内容而非通知本身。
原文全文
展开原文 · 1,141 字
Morgan Stanley Global Healthcare Conference
on
Tuesday, September 15th
at
5:35 p.m. ET
.
An audio webcast of the fireside chat can be accessed on the
Investors
section of Contineum’s website. A webcast replay will also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit
www.contineum-tx.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260825617969/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
on
Tuesday, September 15th
at
5:35 p.m. ET
.
An audio webcast of the fireside chat can be accessed on the
Investors
section of Contineum’s website. A webcast replay will also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit
www.contineum-tx.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260825617969/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。